For the quarter ending 2025-09-30, HRTX made $38,213,000 in revenue. -$17,494,000 in net income. Net profit margin of -45.78%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net product sales | 38,213,000 | 37,200,000 | 38,903,000 | 37,158,333.333 |
| Cost of product sales | 11,914,000 | 9,857,000 | 8,457,000 | 9,730,000 |
| Gross profit | 26,299,000 | 27,343,000 | 30,446,000 | 27,428,333.333 |
| Research and development | 3,470,000 | 2,934,000 | 2,279,000 | 4,072,666.667 |
| General and administrative | 13,980,000 | 14,471,000 | 12,702,000 | 13,674,666.667 |
| Sales and marketing | 12,942,000 | 11,575,000 | 12,311,000 | 12,037,666.667 |
| Total operating expenses | 30,392,000 | 28,980,000 | 27,292,000 | 29,785,000 |
| Loss from operations | -4,093,000 | -1,637,000 | 3,154,000 | -2,356,666.667 |
| Loss on debt extinguishment | -11,339,000 | - | - | - |
| Other expense, net | -2,063,000 | -744,000 | -519,000 | 273,333.333 |
| Interest expense | - | - | - | 1,508,000 |
| Interest income | - | - | - | 721,666.667 |
| Total other (expense) income, net | - | - | - | -513,000 |
| Net loss | -17,495,000 | -2,381,000 | 2,635,000 | -2,910,666.667 |
| Unrealized gain (loss) on short-term investments | 1,000 | -2,000 | -12,000 | - |
| Comprehensive loss | -17,494,000 | -2,383,000 | 2,623,000 | -2,926,666.667 |
| Earnings per share, basic | -0.1 | -0.02 | 0.02 | -0.02 |
| Earnings per share, diluted | -0.1 | -0.02 | 0.01 | -0.02 |
| Weighted average common shares outstanding, basic | 170,348,000 | 154,020,000 | 153,490,000 | -127,000 |
| Weighted average common shares outstanding, diluted | 170,348,000 | 154,020,000 | 196,921,000 | -127,000 |
HERON THERAPEUTICS, INC. DE (HRTX)
HERON THERAPEUTICS, INC. DE (HRTX)